Our year ended with a surplus of €4.887,94, which is slightly lower than the budget of the year (€25.497). The total gross income 2022 is €1.002.556. This is €338.875 below budget for three good reasons. Firstly, we deferred monies onto 2022 to cover the cost for remaining activities and deliverables 2021 for the Atopic Eczema Consensus Europe (€26.105), Breathe Coalition (€39.712) and the DIG_IT (€32.258) projects. Secondly, we further deferred monies saved in lower expenditure than anticipated to support the European Parliament Interest Group project (€66.500). For the same reason, we also deferred €135.761 to support other activities, such as a core project work focusing on food allergy, membership-based activities and important work as the organisation who represents, and advocates change for all people with allergy, asthma and COPD in Europe.
Finally, while EFA can succeed in shifting activities and projects into virtual mode, it is not entirely the same case for EU health research projects we participate in. Activities in the Immuniverse project, which started in the beginning of the pandemic, were delayed. That implies that patient involvement in the project was delayed as well. Since our role is to facilitate the involvement of patients, we could not implement all the activities that we planned, therefore some planned use of monies and income moves to 2022. Similarly, the CURE project was supposed to end in the 2021, but the duration of the contract was prolonged to March 2022, and meant that that the closing event, that EFA led, was also postponed to 2022.
With the new Board, we approved new financial mandates, and arranged governance and daily work accordingly with our day-to-day financial management with the bank and funders.
I started as treasurer in late May 2021. It was my first year in the EFA community, but I felt very welcome and have felt the pleasure of supporting EFA as part of the Board. I see great things happening at European level, that are complementary to what I do on daily basis at Longfonds for Dutch patients and lung research. The monies at EFA are well spent, and together with my colleagues in the board, we look at quarterly financial reports and reflect where we are going. I want to thank all our sustainable corporate partners and the European Commission, individually and collectively for the support for our work.
For the next years, I would like to help develop our anticipation on finances and financial management.
Sincerely,
Yvonne Spies
EFA Treasurer